Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2000

View Archived Issues

Active Biotech updates agreements for traveler's diarrhea vaccines

Insulin demonstrates antiatherosclerotic properties

Trial reveals utility of acupuncture in treating cocaine dependence

Vanadocenes induce germ cell apoptosis in mouse model of testicular cancer

Roche reports synthesis and antitumor activity of Ro-27-0574

Neurokinin antagonists under development for treatment of respiratory diseases

Sigma-1 and sigma-2 receptor ligands developed

Identification of dual Na+/Ca2+ blocker with antioxidant activity reported by Suntory

Synthetic analogues of 1alpha,25-(OH)2D3 may be useful in cancer chemoprevention

DuPont provides funding for large trial of cardiac imaging in diabetic patients

Phase I trial of novel anticancer treatment under way

Opioid receptor ligands under study at Pfizer

New compounds interacting with opioid receptors useful for IBS, etc.

AT1 antagonists in the treatment of CHF

CRF antagonists from DuPont reportedly useful in depression, etc.

Yeda presents new antiretroviral conjugates

New testosterone derivatives patented by Schering AG

FDA approves Advair Diskus for treatment of asthma

Spironolactone improves survival in CHF, possibly by limiting cardiac fibrosis

FDA accepts Celebrex sNDA for filing

Phase II trial to commence for diabetes vaccine

Individuals with manic depression may have lower heart attack risks

Inex broadens Onco TCS clinical trial program

Chymase inhibition -- a route to cardiovascular drug discovery

Taro to market and distribute Periostat in Israel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...